Targets › GPRC3
5 programs from 5 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on GPRC3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| OriCell Therapeutics | Ori-C101 GPC3-directed CAR-T cell therapy | GPRC3 | Phase 1 | Hepatocellular Carcinoma | Dec 2026 |
| AstraZeneca | AZD5851 GPC3-directed CAR-T cell therapy | GPRC3 | Phase 1 | Hepatocellular Carcinoma | Dec 2027 |
| Peking University | OriC902 GPC3-targeted chimeric antigen receptor (CAR) T cell therapy | GPRC3 | Phase 1 | HCC | Dec 2027 |
| Guangzhou FineImmune Biotechnology | Super CAR-T GPC3-targeted CAR-T cell therapy | GPRC3 | Phase 1 | Advanced Hepatocellular Carcinoma (HCC) | Apr 2028 |
| Second Affiliated Hospital of Guangzhou Medical University | GPC3/Mesothelin-CAR-γδT cells GPC3/Mesothelin-targeted CAR-γδT cell therapy | GPRC3, MSLN | Phase 1 | Pancreas Cancer | Nov 2030 |
Hepatocellular Carcinoma (2) Pancreas Cancer (1) Advanced Hepatocellular Carcinoma (HCC) (1) HCC (1)
other (2), protein or peptide (2), small molecule (1)
Second Affiliated Hospital of Guangzhou Medical University (1) AstraZeneca (1) OriCell Therapeutics (1) Guangzhou FineImmune Biotechnology (1) Peking University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.